Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares, totaling 61,073,420.00 CNY, which represents 3.31% of the net profit attributable to ordinary shareholders for the year[6]. - In 2022, the total cash dividends distributed amounted to 977,174,720.00 CNY, accounting for 52.98% of the net profit attributable to ordinary shareholders[6]. - The company intends to issue 0.45 bonus shares for every share held, increasing the total share capital to 442,782,295 shares[7]. - The company's total share capital as of December 31, 2022, was 305,367,100 shares, which serves as the basis for the dividend distribution calculations[171]. - The cash dividend distribution for the first half of 2022 was completed by September 30, 2022[170]. - The company's profit distribution plan has been approved by independent directors, ensuring compliance with company regulations and decision-making procedures[171]. Financial Performance - The company's operating revenue for 2022 reached ¥8,348,772,840.84, representing a year-on-year increase of 28.76% compared to ¥6,483,760,507.83 in 2021[23]. - The net profit attributable to shareholders of the listed company was ¥1,844,424,518.46 in 2022, a significant increase of 125.91% from ¥816,452,808.96 in 2021[23]. - The basic earnings per share for 2022 was ¥6.1257, up 122.83% from ¥2.7490 in 2021[24]. - The company's total assets increased by 14.68% to ¥6,513,098,085.61 at the end of 2022, compared to ¥5,679,443,510.79 at the end of 2021[23]. - The company achieved a net cash flow from operating activities of ¥1,773,699,279.71 in 2022, an increase of 78.48% from ¥993,795,032.81 in 2021[23]. - The weighted average return on net assets for 2022 was 60.85%, an increase of 24.17 percentage points from 36.68% in 2021[24]. Risk Management - The company has outlined various risks including safety, environmental, market fluctuations, and raw material price volatility in its management discussion[11]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in the report[8]. - The company faces risks related to safety, environmental protection, industry policies, market fluctuations, and exchange rates[122]. - The company will enhance safety management and conduct comprehensive risk analysis to ensure stable production operations[123]. Research and Development - The company is focusing on innovation by increasing R&D investments in key intermediates, flame retardants, and nano new materials to ensure long-term development[35]. - The total R&D expenditure amounted to 263,536,551.05 yuan, representing 3.16% of total revenue[63]. - Research and development expenses increased by 11.06% to 263.54 million RMB, reflecting the company's commitment to innovation[49]. - The company applied for 29 patents in 2022, including 2 international patents, and received authorization for 15 patents[85]. - The company invested CNY 263.54 million in R&D in 2022, with 13 new projects initiated and 20 ongoing projects, resulting in 14 project outputs and 6 projects carried over to 2023[85]. Environmental Management - The company invested CNY 11,989,000 in environmental protection during the reporting period[183]. - A total of 62 environmental improvement projects were implemented, focusing on VOCs reduction, wastewater reduction, and dust control[184]. - The company achieved compliance with wastewater discharge standards, with COD emissions averaging 283.9 mg/L against a limit of 500 mg/L[187]. - The company maintained stable operation of all environmental protection facilities, ensuring compliance with emission standards[185]. - The company reported a decrease in emissions of major pollutants such as sulfur dioxide and nitrogen oxides compared to the previous year[184]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[193]. Governance and Compliance - The company has established a long-term mechanism to prevent major shareholders from infringing on the interests of the listed company[129]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[130]. - The company emphasizes transparency in information disclosure, ensuring all shareholders have equal access to information[132]. - The company has revised its governance structure to ensure compliance with legal requirements and protect shareholder rights, particularly for minority shareholders[128]. Market Expansion and Strategy - The company is focusing on expanding its market presence through precise layout and scientific positioning, aiming to enhance sales scale[36]. - The company is enhancing its marketing strategies to stabilize sales volume and expand the sales area, variety, and volume of formulations[118]. - The company plans to advance the construction of its second and third production bases and implement key projects, including a 100,000-ton intelligent formulation project[113]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $300 million earmarked for potential deals[146]. Leadership and Management - The company has seen leadership changes with Pang Changguo becoming the Chief Engineer in January 2023 after various roles since November 2011[148]. - The company reported a significant leadership presence in the agricultural technology sector, with Zhang Hua as Chairman of multiple subsidiaries since September 2021[149]. - The company has a strong management team with members holding key positions in shareholder units, such as Gu Jian Guo as Deputy Secretary and General Manager since December 2020[149]. - The leadership team has been stable, with many members serving in their roles for several years, ensuring continuity in management[148]. Employee Management - Employee motivation initiatives are being strengthened through stock incentives and positive reinforcement to enhance company cohesion[38]. - The company plans to implement a 40% key position training program and a 20% job rotation plan to cultivate backup talent[169]. - The company is focused on optimizing its salary system and implementing differentiated assessments for marketing and R&D personnel[167]. - A total of 53 young backbone employees were promoted, and 36 key positions were newly appointed during the reporting period[169].

二、 说明会召开的时间、地点 证券代码：600389 证券简称：江山股份 公告编号：临 2023-012 南通江山农药化工股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南通江山农药化工股份有限公司（以下简称"公司"）拟于 2023 年 4 月 18 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 4 月 21 日下午 15:00-16:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 （一） 会议召开时间：2023 年 04 月 21 日 下午 15:00-16:00 1 会议召开时间：2023 年 4 月 21 日(星期五) 下午 15:00-16:00 会 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：600389 证券简称：江山股份 南通江山农药化工股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |-------------------------------------------|------------------|---------------------------|----------------------------------------|----------- ...

2022 年半年度报告 公司代码：600389 公司简称：江山股份 南通江山农药化工股份有限公司 2022 年半年度报告 1 / 167 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人薛健、主管会计工作负责人宋金华及会计机构负责人（会计主管人员）顾玉宝声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2022年半年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分 配方案如下：上市公司拟向全体股东每10股派发现金红利30.00元（含税）。截至2022年6月30日 ，公司总股本305,367,100股，以此计算合计拟派发现金红利916,101,300.00元（含税）。 上述分配预案需提交公司2022年第一次临时股东大会审议批准。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未 ...

2021 年年度报告 公司代码：600389 公司简称：江山股份 南通江山农药化工股份有限公司 2021 年年度报告 1 / 201 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人薛健、主管会计工作负责人宋金华及会计机构负责人（会计主管人员）顾玉宝声 明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 鉴于2021年半年度已向公司全体股东每 10 股派发现金红利 10.00 元(含税), 合计派发现 金红利 297,000,000.00 元（含税），占本年度合并报表中归属于上市公司普通股股东的净利润 比例为36.38%，2021年末不再进行利润分配，也不进行公积金转增股本。 上述分配预案需提交公司2021年年度股东大会审议批准。 六、 前瞻性陈述的风险声明 √适用 □不 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600389 证券简称：江山股份 南通江山农药化工股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人薛健、主管会计工作负责人宋金华及会计机构负责人（会计主管人员）顾玉宝保证季 度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|------------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 \n变动幅度 (%) | | 营业收入 | ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600389 证券简称：江山股份 南通江山农药化工股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------|------------------------------|-----------------------------------------------| ...

2021 年半年度报告 公司代码：600389 公司简称：江山股份 南通江山农药化工股份有限公司 2021 年半年度报告 1 / 161 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人薛健、主管会计工作负责人叶洪林及会计机构负责人（会计主管人员）顾玉宝声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年半年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分 配方案如下：上市公司拟向全体股东每10股派发现金红利10.00元（含税）。截至2021年6月30日 ，公司总股本297,000,000股，以此计算合计拟派发现金红利297,000,000.00元（含税）。 上述分配预案需提交公司2021年第一次临时股东大会审议批准。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划 ...

Financial Performance - The company's operating revenue for 2020 was CNY 5,121,357,779.17, representing a 7.11% increase from CNY 4,781,182,239.01 in 2019[21] - The net profit attributable to shareholders of the listed company was CNY 334,934,906.61, an increase of 11.62% compared to CNY 300,061,162.27 in 2019[21] - The net cash flow from operating activities reached CNY 707,172,745.86, showing a significant increase of 72.87% from CNY 409,081,587.64 in 2019[21] - The total assets of the company at the end of 2020 were CNY 4,595,614,577.48, a 6.72% increase from CNY 4,306,243,931.02 at the end of 2019[21] - The net assets attributable to shareholders of the listed company decreased by 1.82% to CNY 1,978,368,884.15 from CNY 2,015,003,957.26 in 2019[21] - Basic earnings per share for 2020 was CNY 1.1277, an increase of 11.62% compared to CNY 1.0103 in 2019[22] - The weighted average return on equity rose to 16.30% in 2020, up 0.68 percentage points from 15.62% in 2019[22] Revenue and Sales - Total revenue for the first quarter of 2020 was CNY 1,243,898,295.96, while the second quarter revenue was CNY 1,466,772,641.44[25] - Net profit attributable to shareholders for the second quarter of 2020 was CNY 113,668,863.78, showing an increase from CNY 97,823,441.89 in the first quarter[25] - Revenue from pesticide products reached CNY 3.017 billion, an increase of CNY 238 million, with a growth rate of 8.58%[50] - The revenue from domestic sales reached ¥3,622,346,639.53, reflecting a 16.72% increase compared to the previous year[58] - The revenue from the chemical segment decreased by 4.57% year-on-year, with a gross profit margin of 24.96%[58] - The company’s insecticides, including dichlorvos and carbofuran, utilize clean production processes, ensuring high product quality and stability[89] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 5.00 per 10 shares, totaling CNY 148,500,000.00, subject to approval at the annual shareholders' meeting[6] - The company distributed a cash dividend of 3.10 RMB per 10 shares for the 2019 fiscal year, totaling 92,070,000 RMB, and a cash dividend of 10.00 RMB per 10 shares for the first half of 2020, totaling 297,000,000 RMB[140] - In 2020, the company reported a net profit attributable to ordinary shareholders of 334,934,906.60 RMB, with a cash dividend payout ratio of 44.34% for the full year and 88.67% for the first half[141] Operational Efficiency and Costs - The company reported a significant decrease in sales expenses by 59.86%, attributed to the adjustment of product transportation costs to operating costs under the new revenue recognition standards[54] - The company plans to optimize its product structure and increase production capacity utilization to reduce manufacturing costs[135] - The company has adjusted its strategy to enhance production efficiency and reduce costs while expanding the sales of chemical intermediates to improve economic benefits[90] Research and Development - The company invested CNY 169.38 million in R&D in 2020, with 15 new projects initiated and 24 ongoing projects[97] - The number of R&D personnel was 471, making up 27.48% of the total workforce[73] - The company developed 15 new formulation products, with 8 completing field trials and 10 ready for sale, while initiating 15 new domestic registrations and 56 new international registrations[98] Environmental Management - The company has implemented over 60 environmental improvement projects, focusing on VOCs reduction and dust control, and has been recognized as a "Green Factory" in Jiangsu Province[196] - The company has maintained compliance with environmental discharge standards, with no incidents of exceeding discharge limits reported[196] - The company has committed to a circular economy development model, aiming to reduce emissions and enhance resource utilization[196] Risk Management - The company has identified risks related to industry policy changes, market fluctuations, raw material price volatility, and environmental regulations[8] - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in the report[7] - The company faces risks from market fluctuations in the pesticide industry, including increased competition and potential price declines[136] Strategic Initiatives - The company is actively pursuing strategic collaborations with key clients to optimize customer structure and enhance operational efficiency[46] - The company aims to enhance its research and development capabilities and improve resource utilization to form a competitive product series with stable profitability[128] - The company plans to implement differentiated marketing strategies and optimize its domestic and overseas sales networks to achieve annual marketing goals[130] Corporate Governance - The company has maintained a standard unqualified audit report from its accounting firm, indicating the accuracy and completeness of its financial statements[5] - The company guarantees compliance with laws and regulations, ensuring that it will not exploit its shareholder position for improper benefits or engage in actions detrimental to the listed company and its minority shareholders[147] - The company has not reported any major accounting errors or corrections during the reporting period[161]

Financial Performance - Net profit attributable to shareholders of the listed company was CNY 116,948,228.54, an increase of 19.55% year-on-year[12]. - Operating revenue for the period reached CNY 1,554,030,577.77, reflecting a growth of 24.93% compared to the same period last year[12]. - Basic earnings per share rose to CNY 0.3938, up 19.55% from CNY 0.3294 in the previous year[12]. - Net profit for Q1 2021 was ¥121,461,305.26, representing a 22.0% increase from ¥99,586,966.56 in Q1 2020[51]. - Earnings per share for Q1 2021 were ¥0.3938, compared to ¥0.3294 in Q1 2020, reflecting a growth of 19.6%[51]. Cash Flow - The net cash flow from operating activities was CNY -77,762,518.43, an improvement of 47.87% from CNY -149,158,341.26 in the previous year[12]. - Net cash flow from operating activities improved to -¥77,762,518.43 from -¥149,158,341.26, indicating a positive trend[28]. - Cash flow from operating activities in Q1 2021 was negative at -¥77,762,518.43, an improvement from -¥149,158,341.26 in Q1 2020[60]. - The total operating cash inflow for Q1 2021 was 993,690,035.16 RMB, an increase from 773,106,216.70 RMB in Q1 2020[62]. - The company reported a net increase in cash and cash equivalents of -242,489,688.60 RMB for Q1 2021, compared to -25,715,016.96 RMB in Q1 2020[64]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,516,954,572.61, a decrease of 1.71% compared to the end of the previous year[12]. - Significant changes in financial indicators included a 34.38% decrease in cash and cash equivalents, totaling CNY 558,056,706.03[18]. - The company’s total liabilities decreased to ¥2,214,100,743.34 from ¥2,397,902,938.72, a reduction of approximately 7.7%[44]. - Total equity increased to ¥2,020,867,788.96 in Q1 2021, up from ¥1,946,851,476.48 in Q1 2020, marking an increase of about 3.8%[44]. - The company’s total liabilities included short-term borrowings of 528,410,362.47 RMB as of Q1 2021[66]. Shareholder Information - The total number of shareholders at the end of the reporting period was 12,494[17]. - The largest shareholder, Nantong Industrial Holding Group Co., Ltd., held 29.30% of the shares[17]. Changes in Financial Indicators - Current liabilities decreased significantly from ¥2,333,670,619.46 to ¥1,825,932,854.24, a reduction of about 21.8%[36]. - Non-current liabilities increased from ¥229,374,345.20 to ¥531,918,133.60, an increase of approximately 132.5%[38]. - Cash and cash equivalents decreased from ¥787,095,249.88 to ¥529,037,120.41, a decline of about 32.8%[40]. - The company reported a significant increase in long-term borrowings from ¥85,463,296.70 to ¥385,463,296.70, an increase of approximately 351.5%[38]. Income and Expenses - Investment income decreased by 38.72% to ¥11,077,694.52 from ¥18,078,362.15, primarily due to lower profits from joint ventures[22]. - Income tax expenses increased by 59.79% to ¥22,671,708.47 from ¥14,188,025.04, attributed to higher profits during the reporting period[22]. - Total operating costs for Q1 2021 were ¥1,422,334,942.80, up 24.8% from ¥1,140,113,263.76 in Q1 2020[49]. - Research and development expenses for Q1 2021 were ¥43,208,304.11, a decrease of 10.5% from ¥48,523,619.69 in Q1 2020[49]. Compliance and Standards - The company adopted the new leasing standards effective January 1, 2021, resulting in an increase of ¥6,447,793.22 in both right-of-use assets and lease liabilities[79]. - The company did not apply retrospective adjustments for prior comparative data under the new leasing standards[80]. - The company has not issued an audit report for this period[80].